论文部分内容阅读
目的总结探讨腹膜假性黏液瘤治疗的经验及预后。方法回顾性分析1990年1月至2007年12月第二军医大学长海医院收治的42例腹膜假性黏液瘤病人的治疗及随访情况。结果42例病人均经手术治疗,其中23例仅行细胞减灭术(CRS组),19例行细胞减灭术及术中腹腔温热化疗(CRS+IPHC组)。全部病人无手术死亡,随访1～16(平均6.8)年。其中CRS+IPHC组与CRS组的1年存活率比较差异无统计学意义(P>0.05),CRS+IPHC组3、5年存活率显著高于CRS组(P<0.05),复发率显著低于CRS组(P<0.05)。结论细胞减灭术辅以术中腹腔温热化疗可提高腹膜假性黏液瘤病人的存活率。
Objective To summarize the experience and prognosis of peritoneal pseudomyxoma treatment. Methods A retrospective analysis of the treatment and follow-up of 42 patients with peritoneal pseudomyxoma admitted to Changhai Hospital from the Second Military Medical University from January 1990 to December 2007 was performed. RESULTS: Forty-two patients were treated with surgery. Of these patients, 23 underwent cytoreductive surgery alone (CRS group), 19 underwent cytoreductive surgery and intraoperative abdominal hyperthermic chemotherapy (CRS+IPHC group). All patients had no operative death and were followed up for 1 to 16 (mean 6.8) years. There was no significant difference in the 1-year survival rate between the CRS+IPHC group and the CRS group (P>0.05). The 3 and 5-year survival rates in the CRS+IPHC group were significantly higher than those in the CRS group (P<0.05), and the recurrence rate was significantly lower. In the CRS group (P<0.05). Conclusion Cytoreductive surgery combined with intraoperative intraperitoneal hyperthermic chemotherapy can improve the survival rate of patients with peritoneal pseudomyxoma.